Participated · Series A · Sep 2025

Visana Health operates a nationwide virtual medical home for women ages 18-65, covering everything from menstruation to menopause and complex conditions such as endometriosis and PCOS. The company partners with national and regional health plans as well as more than 40 self-funded employers, extending access to over 35 million covered lives and 1 million employees. Actuarial analyses show its value-based model lowers employer medical costs by 34 %, reduces unnecessary procedures by 78 %, and saves more than $2,400 per enrollee annually, yielding a 4:1 ROI. Visana’s 50-state medical group expects to serve nearly 50,000 women in 2025. Newly raised capital will allow it to broaden services into weight loss, cardiometabolic care, and chronic disease management while investing in AI to streamline provider workflows. The company is headquartered in Minneapolis.

Led · Series A · Jun 2025

Autonomize AI offers an Agentic AI Orchestration platform with pre-trained, ready-to-deploy AI agents that coordinate as intelligent copilots across regulated healthcare workflows. The platform is healthcare-native, emphasizing explainability, human-in-the-loop workflows, and enterprise-wide orchestration rather than generic generative AI. Its agents address use cases such as care management, utilization management, benefits checks, and chart reviews, and are reported to deliver measurable operational impact at scale. Reported operating metrics include 36,000 clinical hours saved per month, 100,000+ automated care plans created monthly, and up to 50% faster decisions for prior authorizations and claims. Customers include Top 20 Pharmaceuticals, Fortune 100 healthcare enterprises, and life sciences companies. The company says it will use new funding to scale the platform and further rewire healthcare operations to reduce clinician burden and improve patient outcomes. Autonomize AI provides a secure, cloud-based AI platform optimized for healthcare and life sciences that ingests multi-modal and unstructured medical data using pre-trained medical LLMs. Its product suite includes Autonomize Pixel for clinical-trial workflows and patient matching, Autonomize Wizard for multi-modal chart insights, and generative-AI capabilities for conversational search and summarization of internal data. The platform supports fine-tuning on private data, deployment into virtual private clouds, and a privacy filter that anonymizes PII and PHI. Launched in 2022 and headquartered in Austin, Texas, the company emphasizes human-centered workflows to augment knowledge workers and improve operational efficiency. Customers report rapid ROI and efficiency gains—SubjectWell said medical-records review became ten times more efficient and accurate. Autonomize AI plans to use new funding to boost R&D and commercialization to drive down costs and accelerate adoption across healthcare organizations.

Led · Series A · Feb 2024

Founded in 2021 and headquartered in San Diego, 9amHealth provides AI-enabled virtual specialty care for conditions such as obesity, diabetes, hypertension, and dyslipidemia. The company offers an integrated model combining specialized clinicians (including endocrinologists and obesity medicine specialists), at-home lab testing, medication management, and continuous care. 9amHealth partners with employers, health plans, and pharmacy benefit managers and reports more than $50 million in projected medical and pharmacy savings across two Fortune 100 employers. It has delivered pharmacy cost savings amid rising demand for GLP-1 therapies while improving engagement and clinical outcomes. Backed by investors including Define Ventures, SemperVirens VC, 7Wire Ventures, and The Cigna Group Ventures, the company plans to expand its platform to manage a broader set of high-cost, specialty-level chronic conditions.

Led · Series C · Jun 2023

Octave operates a modern behavioral health practice with in-person and virtual clinics and offers evidence-based, in-network therapy services. The company provides personalized care plans that can include individual, couples, and family therapy and has pioneered payer relationships to make care more affordable through insurance. Led by CEO Sandeep Acharya, Octave was launched in 2018 and currently serves California, Connecticut, Florida, New Jersey, New York, Texas, and Washington, D.C. The company raised a $52M Series C, bringing total funding to $86M. Octave intends to use the funds to drive national expansion of its therapy services and to release new technology products for payer and provider partners. It aims to expand to more regions later in the year and reach all 50 states in 2024. Octave is a San Francisco-based behavioral health company that provides care through in-person and virtual coaching, and individual, relationship and group therapy. Led by co-founder and CEO Sandeep Acharya, the company launched its evidence-based therapy and coaching practice in New York in 2018. It now serves clients across California and New York. Octave raised $20M in a Series B to support technology and clinical innovation and the expansion of business operations. The company intends to use the funding to advance its technology and clinical offerings and to scale operations. Investors in the round include Health Velocity Capital, Cigna Ventures and existing backers such as Greycroft, Obvious Ventures, Company Ventures and Felicis Ventures. Octave is an evidence-based behavioral health practice and wellness community that provides in-person and virtual coaching, group therapy, psychiatry, and content and assessment tools to support clients between sessions. Since opening its first New York office in October 2018, Octave has launched group sessions for anxiety, LGBTQ patients, and expecting couples, and expanded virtual coaching nationwide and internationally. The company uses technology to increase access to care with 30-minute virtual coaching and 45-minute in-person therapy sessions designed to fit busy schedules. Octave plans to increase staff therapists and triple its provider base in the coming months, and will begin offering a variety of free classes for members. It is opening a San Francisco location at 625 Market Street and a second New York office in the Flatiron Building, with additional California and New York locations planned next year. Octave also announced an in-network partnership with Anthem Blue Cross of California, becoming the first startup in the space to be in-network with a major payer. Octave, founded by Sandeep Acharya (formerly head of strategy at One Medical), operates a mental health studio that provides individual therapy, a stress management coaching program, and daily drop‑in classes. Drop‑in classes start at $15 per class, coaching is $75 per session, and ongoing therapy is $180 per session. Octave conducts an intake call within a couple of days and aims to get people seen by a therapist within a couple of weeks. The studio does not take insurance, though many insurers may offer reimbursement. Octave is designed to serve people who do not already have an ongoing relationship with a therapist, while still allowing those in therapy to use classes or coaching. Its first studio is in New York City, and the company plans to operate six to eight locations within the next two years. Octave has raised an undisclosed seed round from Felicis Ventures and angel investors.

Participated · Equity · May 2023

Prognos Health is a New York City–based real-world data (RWD) company operating a managed, integrated RWD marketplace. Its platform harmonizes lab and health records across more than 325 million de-identified patients to provide a comprehensive, integrated view of patient health. The marketplace is used by over 70 life sciences customers to accelerate drug development, improve the safety and efficacy of existing drugs, and identify new patient populations. Led by CEO Sundeep Bhan, Prognos serves researchers, payers, and providers with fully integrated datasets to support clinical and commercial decision-making. The company raised $23M in growth equity and intends to use the funds to accelerate growth and expand the reach of its platform. The article emphasizes the company’s focus on expanding its impact on healthcare through data-driven tools and partnerships. Medivo operates a HIPAA-compliant, cloud-based health monitoring platform that provides modules for physicians and patients across a range of conditions and offers mobile tools and simple explanations of lab results. The company provides free services for physicians and consumers and has expanded its reach with increased engagements with life sciences firms and a partnership with the American Association of Clinical Endocrinologists. Medivo reports having doubled its growth year-over-year for the past three years and has presented peer-reviewed findings from a proprietary clinical database. The platform includes modules for diabetes, dyslipidemia, hepatitis C, gout, low testosterone, irritable bowel disease, hereditary angioedema, chronic myelogenous leukemia and other conditions, with initiatives to add obesity, rheumatoid arthritis, hepatitis B, HIV, several cancers, and additional chronic diseases. The company plans to continue expanding its network of laboratories, enrich its analytics services, build connectivity to additional data sources, and broaden product offerings and patient engagement services. Medivo is New York City–based and is venture-backed by investors including Merck GHIF, Safeguard Scientifics, and MentorTech Ventures. Medivo provides data analytics and lab testing services through an online, HIPAA‑compliant platform that connects patients to a nationwide network of physicians, lab service centers, and home testing services. Its PatientPath™ services identify gaps in patient lab testing and treatment, enable testing through thousands of labs, explain results to patients, and relay information to primary care physicians. The platform is designed to improve access to testing, educate patients about results, and help physicians make more efficient use of diagnostic testing. Medivo’s stated mission is to save lives through faster and easier access to quality healthcare; the company is led by co‑founder and CEO Sundeep Bhan. The article positions Medivo to capitalize on a U.S. lab testing market described as more than $50 billion and expected to double by 2020, noting lab services affect roughly 70% of critical clinical decisions. The company announced a $7 million Series A to support product development and expansion of sales and marketing.